$GOOGL
This sell-off was excessive. Higher capital expenditures are seen as a long-term AI investment, and huge TPU demand and cloud computing growth are expected to drive future gains. π
$CAPR Bull thesis π
The debate isnβt whether Deramiocel works β itβs about timing and labeling.
Strong physician support, no identified BLA issues, and a first-in-class therapy could create a major catalyst if FDA approval comes through.
$BATL bull thesis π₯
Debt reduction + higher production + rising oil prices + low float creates a potential squeeze setup.
Bulls believe the company could move from turnaround story to debt-free oil producer. π
$RDDT challenging $GOOGL would be a major signal. You donβt risk your biggest traffic partner without a plan. If Reddit is making this move, something bigger may be happening behind the scenes. π
$SMCI π AI server demand is back.
$ 60B+ new orders + margin recovery changed the narrative.
Key levels: $28 support | $31 breakout | $35-$40 upside targets.
Donβt chase the first spike β watch the retest.
$BULL π
Webull is leaning into AI-powered investing while customer assets and trading activity continue expanding.
Growth catalysts:
β AI tools
β Global expansion
β Stronger user deposits
The market now wants one thing: execution.
$CELH π
Building a base after a major reset.
Key levels:
Support: $28 / $25
Resistance: $31 / $35
Hold $28 = bulls still have a shot.
Break $31 with volume could trigger the next momentum move.
Patience > chasing.
$ONDS π
New catalyst: Ondas secured a $6.9M Australian defense contract for counter-UAS systems.
DZYNE acquisition is turning ONDS into an AI defense & autonomous systems play.
The story is strong β now the market wants execution.
$SLNH π
Volume breakout confirmed. Price reclaimed $1.30 and is testing $1.45 resistance.
Key levels:
Support: $1.30 / $1.15
Resistance: $1.45 / $1.60
Hold above $1.30 = bulls stay in control. Break $1.45 with volume could trigger the next leg higher.
$ASTS π
$1B convertible debt raise pressured shares, but the long-term thesis remains intact.
BlueBird deployment, telecom partnerships, and direct-to-phone satellite service are the key catalysts.
Short-term pain, long-term space connectivity story still alive.
$IOVA π¨
Iovance is gaining attention as investors focus on Amtagvi commercialization and improving fundamentals.
2026 revenue guidance: $350Mβ$370M
Cash runway expected into 2028.
The next catalyst: sales growth + pipeline expansion. π§¬π
#Biotech#CancerTherapy
$BMNR π¨
BitMine just repurchased ~5.5M shares at $15.62 avg under its $4B buyback program.
ETH holdings now near 5.78M tokens, approaching the 5% supply target.
Management is shifting capital between ETH accumulation and shareholder .Nextcatalyst: buyback pace + ETH momentum. π
$ZBCN's value lies not in token burning, but in its growing practical applications. Short-term token burning may attract attention, but long-term growth requires user support, trading volume, and ecosystem development. Remain optimistic about ZBCN's long-term potential. π